Assessing early changes in plasma HER2 levels is useful for predicting therapeutic response in advanced breast cancer: A multicenter, prospective, noninterventional clinical study
Open Access
- 24 October 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (5), 5323-5333
- https://doi.org/10.1002/cam4.5352
Abstract
Background Early prediction of treatment response is crucial for the optimal treatment of advanced breast cancer. We aimed to explore whether monitoring early changes in plasma human epidermal growth factor receptor 2 (HER2) levels using digital PCR (dPCR) could predict the treatment response in advanced breast cancer. Methods This was a multicenter, prospective, noninterventional clinical study of patients with advanced breast cancer. All enrolled patients underwent blood testing to measure the HER2 levels by digital PCR before treatment initiation and once every 3 weeks during the study. The primary endpoints were(a) the diagnostic value of dPCR for detecting HER2 status in the blood and(b) the relevance of potential changes in the plasma HER2 level at 3 weeks from baseline for predicting treatment response. Results Overall, 85 patients were enrolled between October 9, 2018, and January 23, 2020. dPCR had a specificity of 91.67% (95% CI: 80.61% to 97.43%) for detecting HER2 amplification, and the area under the receiver operating characteristic (ROC) curve was 0.84 (p < 0.01). A clinically relevant specificity threshold of approximately 90%, which was equivalent to a >= 15% decrease in the plasma HER2 ratio at 3 weeks from baseline, showed a positive predictive value of 97.37% (95% CI: 77.11% to 98.65%) in terms of predicting clinical benefit. Patients whose plasma HER2 ratio was reduced by >= 15% had a longer median progression-free survival (PFS) than those whose ratio was reduced by <15% (9.20 months vs. 4.50 months, p < 0.01). Conclusions Early changes in the plasma HER2 ratio may predict the treatment response in patients with advanced breast cancer and could facilitate optimal treatment selection.Keywords
Funding Information
- National Natural Science Foundation of China (81672634, 82172650)
This publication has 25 references indexed in Scilit:
- Quantitative Analysis of HER2 Amplification by Droplet Digital PCR in the Follow-Up of Gastric Cancer Patients Being Treated with Trastuzumab after SurgeryGastroenterology Research and Practice, 2019
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateJournal of Clinical Oncology, 2018
- HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancerBreast Cancer, 2018
- Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer PatientsTargeted Oncology, 2017
- Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samplesExperimental and Molecular Pathology, 2016
- Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancerGastric Cancer, 2016
- Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic diseaseEMBO Molecular Medicine, 2015
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerThe New England Journal of Medicine, 2015
- Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?Biomarkers in Cancer, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009